Shed announced a definitive commercial agreement with LTR Pharma to commercialize ROXUS®, LTR Pharma’s rapid-onset intranasal erectile dysfunction treatment, across the U.S. The news formalizes the partnership and supports near-term commercial execution, which is modestly positive but unlikely to materially move broader markets.
Shed announced a definitive commercial agreement with LTR Pharma to commercialize ROXUS®, LTR Pharma’s rapid-onset intranasal erectile dysfunction treatment, across the U.S. The news formalizes the partnership and supports near-term commercial execution, which is modestly positive but unlikely to materially move broader markets.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
